|
MX359634B
(es)
|
2011-12-21 |
2018-10-03 |
Novira Therapeutics Inc |
Agentes antivirales contra la hepatitis b.
|
|
EP2890688A1
(en)
|
2012-08-28 |
2015-07-08 |
Janssen Sciences Ireland UC |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
EA027068B1
(ru)
|
2013-04-03 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
ES2695182T3
(es)
|
2013-05-17 |
2019-01-02 |
Janssen Sciences Ireland Uc |
Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B
|
|
HUE039152T2
(hu)
|
2013-07-25 |
2018-12-28 |
Janssen Sciences Ireland Uc |
Glioxamiddal szubsztituált pirrolamid-származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerként
|
|
JP6452119B2
(ja)
|
2013-10-23 |
2019-01-16 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
CA2936947A1
(en)
|
2014-02-05 |
2015-08-13 |
Novira Therapeutics, Inc. |
Combination therapy for treatment of hbv infections
|
|
WO2015118057A1
(en)
|
2014-02-06 |
2015-08-13 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
BR112017007662B1
(pt)
|
2014-12-18 |
2021-11-03 |
F. Hoffmann-La Roche Ag |
Composto, composição farmacêutica e uso de um composto
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
US9884831B2
(en)
|
2015-03-19 |
2018-02-06 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis B infections
|
|
CA2988620A1
(en)
*
|
2015-06-16 |
2016-12-22 |
Jiangsu Hengrui Medicine Co., Ltd. |
Piperidine derivative and preparation method and pharmaceutical use thereof
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US10077239B2
(en)
|
2015-09-29 |
2018-09-18 |
Novira Therapeutics, Inc. |
Crystalline forms of a hepatitis B antiviral agent
|
|
RU2745742C1
(ru)
*
|
2015-10-01 |
2021-03-31 |
Олема Фармасьютикалз, Инк. |
ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
|
|
US10519148B2
(en)
|
2015-11-12 |
2019-12-31 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Acrylic acid derivative, preparation method and use in medicine thereof
|
|
US10118910B2
(en)
|
2015-12-09 |
2018-11-06 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective estrogen receptor downregulators
|
|
AU2016379672A1
(en)
|
2015-12-22 |
2018-06-21 |
Jiangsu Hengrui Medicine Co., Ltd. |
Benzopiperidine derivative, preparation method thereof and medical use thereof
|
|
JP6905539B2
(ja)
*
|
2016-02-05 |
2021-07-21 |
インベンティスバイオ リミテッド ライアビリティ カンパニー |
選択的エストロゲン受容体分解剤およびその使用
|
|
CN112679495B
(zh)
|
2016-04-01 |
2023-03-28 |
里科瑞尔姆Ip控股有限责任公司 |
雌激素受体调节剂
|
|
AU2017248828A1
(en)
|
2016-04-15 |
2018-11-01 |
Janssen Sciences Ireland Uc |
Combinations and methods comprising a capsid assembly inhibitor
|
|
US10125135B2
(en)
|
2016-04-20 |
2018-11-13 |
Astrazeneca Ab |
Chemical compounds
|
|
IL262643B2
(en)
|
2016-04-29 |
2023-09-01 |
Univ Texas |
Targeted measurement of hormone receptor-associated transcriptional activity
|
|
WO2017197904A2
(zh)
*
|
2016-05-08 |
2017-11-23 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
JP7018026B2
(ja)
*
|
2016-06-16 |
2022-02-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロアリールエストロゲン受容体モジュレーター及びその使用
|
|
WO2017216280A1
(en)
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
CN109415361B
(zh)
*
|
2016-06-29 |
2022-03-08 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
AU2017290748A1
(en)
|
2016-07-01 |
2019-01-17 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
|
TW201815789A
(zh)
|
2016-07-25 |
2018-05-01 |
瑞典商阿斯特捷利康公司 |
化合物
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
CN110139674B
(zh)
*
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
|
TWI735681B
(zh)
|
2016-10-24 |
2021-08-11 |
瑞典商阿斯特捷利康公司 |
化合物
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
IL267795B2
(en)
|
2017-01-06 |
2023-02-01 |
G1 Therapeutics Inc |
Combination therapy for the treatment of cancer
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
SG11201906767XA
(en)
|
2017-01-30 |
2019-08-27 |
Astrazeneca Ab |
Estrogen receptor modulators
|
|
WO2018148440A1
(en)
|
2017-02-08 |
2018-08-16 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
US10208011B2
(en)
|
2017-02-10 |
2019-02-19 |
G1 Therapeutics, Inc. |
Benzothiophene estrogen receptor modulators
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
EP3641762A4
(en)
|
2017-06-20 |
2021-03-10 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
|
|
WO2018233591A1
(zh)
*
|
2017-06-20 |
2018-12-27 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
RU2019142591A
(ru)
|
2017-06-29 |
2021-07-29 |
Г1 Терапьютикс, Инк. |
Морфологические формы g1t38 и способы их получения
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
*
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
JP7348663B2
(ja)
*
|
2018-02-23 |
2023-09-21 |
センター フォー インテリジェント リサーチ イン クリスタル エンジニアリング，エセ．エレ． |
ユビキノールの共結晶及びそれらを含む組成物
|
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
|
EA202092436A1
(ru)
|
2018-05-14 |
2021-05-04 |
Нувейшн Био Инк. |
Противораковые соединения, нацеливающие на ядерные гормональные рецепторы
|
|
WO2019228443A1
(en)
*
|
2018-05-30 |
2019-12-05 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Selective estrogen receptor downregulators and uses thereof
|
|
DK3810283T3
(en)
|
2018-06-21 |
2023-08-21 |
Hoffmann La Roche |
Faste former af tartratsalt af 3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluorpropan-1-ol, proces¿..
|
|
AU2019299221A1
(en)
|
2018-07-03 |
2021-02-04 |
The Board Of Trustees Of The University Of Illinois |
Activators of the unfolded protein response
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
MX2021007687A
(es)
|
2018-12-24 |
2021-10-13 |
Inventisbio Co Ltd |
Sales novedosas de degradadores selectivos de receptores de estrogeno.
|
|
AU2020223865A1
(en)
|
2019-02-22 |
2021-07-15 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
TW202108576A
(zh)
|
2019-05-06 |
2021-03-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物
|
|
MX2021013774A
(es)
|
2019-05-14 |
2021-12-10 |
Nuvation Bio Inc |
Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
|
|
CA3144791A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
MX2022001149A
(es)
|
2019-08-06 |
2022-04-06 |
Recurium Ip Holdings Llc |
Moduladores del receptor de estrógeno para el tratamiento de mutantes.
|
|
MX2022005139A
(es)
*
|
2019-11-04 |
2022-06-24 |
Recurium Ip Holdings Llc |
Sales y formas de un modulador de receptores estrogénicos.
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2021127561A1
(en)
|
2019-12-20 |
2021-06-24 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
CA3164166A1
(en)
|
2020-01-10 |
2021-07-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
|
|
CN119823124A
(zh)
|
2020-03-05 |
2025-04-15 |
C4医药公司 |
用于brd9的靶向降解的化合物
|
|
ES3044433T3
(en)
|
2020-03-06 |
2025-11-26 |
Olema Pharmaceuticals Inc |
Compositions for use in a method of treating an estrogen receptor associated cancer
|
|
AU2021260109B2
(en)
|
2020-04-24 |
2024-07-11 |
Astrazeneca Ab |
Pharmaceutical formulations
|
|
EP4138834A1
(en)
|
2020-04-24 |
2023-03-01 |
Astrazeneca AB |
Dosage regimen for the treatment of cancer
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
BR112023002161A2
(pt)
*
|
2020-08-05 |
2023-04-04 |
Aizant Drug Res Solutions Private Limited |
Formas sólidas de dosagem de palbociclibe
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
US20240002950A1
(en)
|
2020-11-23 |
2024-01-04 |
Sanofi |
Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer
|
|
EP4267578A4
(en)
*
|
2020-12-23 |
2024-11-20 |
Recurium IP Holdings, LLC |
ESTROGEN RECEPTOR MODULATORS
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
EP4334314A1
(en)
|
2021-05-03 |
2024-03-13 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20240018446A
(ko)
|
2021-06-08 |
2024-02-13 |
씨4 테라퓨틱스, 인코포레이티드 |
돌연변이 braf의 분해를 위한 요법
|
|
EP4366734A4
(en)
*
|
2021-07-08 |
2025-05-21 |
Olema Pharmaceuticals, Inc. |
METHODS OF TREATING DISEASES ASSOCIATED WITH ESTROGEN RECEPTOR
|
|
CA3225268A1
(en)
|
2021-07-09 |
2023-01-12 |
Lina Jia |
Salt types of tricyclic tetrahydro isoquinoline derivative
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
CN119998285A
(zh)
|
2022-08-03 |
2025-05-13 |
百时美施贵宝公司 |
用于调控ret蛋白的化合物
|
|
CN120569388A
(zh)
|
2022-11-04 |
2025-08-29 |
百时美施贵宝公司 |
Ret-ldd蛋白降解剂
|
|
CN120530116A
(zh)
|
2022-11-04 |
2025-08-22 |
百时美施贵宝公司 |
Ret-ldd蛋白抑制剂
|
|
WO2024242504A1
(ko)
*
|
2023-05-25 |
2024-11-28 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|